Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.

被引：0
|
作者：
Winton, Elliott F.
Devos, Timothy
Oh, Stephen T.
Platzbecker, Uwe
Wadleigh, Martha
Jun, Susie
Lee, Peter
Deng, Wei
Gupta, Vikas
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] Univ Ziekenhuizen Leuven UZ Leuven, Leuven, Belgium
[3] Washington Univ, St Louis, MO USA
[4] TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Gilead Sci Inc, Foster City, CA USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7101
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
    Gupta, Vikas
    Baer, Maria R.
    Oh, Stephen T.
    Miller, Carole Brennan
    Jun, Susie
    Lee, Peter
    Dong, Hua
    Reiter, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] ReTHINK: A randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
    Passamonti, Francesco
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Reiter, Andreas
    Bharathy, Savita
    Iommazzo, Dana
    Stalbovskaya, Viktoriya
    Gopalakrishna, Prashanth
    Mesa, Ruben A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Efficacy and safety of Elagolix in endometriosis: Phase-III randomized double-blind active-controlled trial
    Gupta, N.
    Palve, T.
    Kamilya, G.
    Srivastava, S.
    Malathi, P.
    Bohir, S.
    Patel, J. S.
    Dash, M. K.
    Saigal, S.
    Savalia, K. P.
    Gupta, T.
    Chaudhary, D.
    Manohar, R.
    Shah, P.
    Bhat, V. V.
    Shetty, A.
    Saha, S.
    Quadros, R.
    Patil, D.
    Patel, P.
    Ghadge, P.
    Mane, A.
    Mehta, S.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 131 : 3 - 3
  • [4] A randomized, double-blind, placebo-controlled phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who have suboptimal response to ruxolitinib
    Yacoub, Abdulraheem
    Stouffs, Michael
    Zhou, Feng
    Assad, Albert
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 112 - 113
  • [5] Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.
    Mascarenhas, John
    Maher, Keri Renee
    Rampal, Raajit
    Bose, Prithviraj
    Podoltsev, Nikolai Alexandrovich
    Hong, Junshik
    Wang, Xulong
    Kye, Steve
    Harrison, Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
    Verstovsek, Srdan
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Al-Ali, Haifa Kathrin
    Lavie, David
    Kuykendall, Andrew T.
    Grosicki, Sebastian
    Iurlo, Alessandra
    Goh, Yeow Tee
    Lazaroiu, Mihaela C.
    Egyed, Miklos
    Fox, Maria Laura
    McLornan, Donal
    Perkins, Andrew
    Yoon, Sung -Soo
    Gupta, Vikas
    Kiladjian, Jean -Jacques
    Granacher, Nikki
    Lee, Sung-Eun
    Ocroteala, Luminita
    Passamonti, Francesco
    Harrison, Claire N.
    Klencke, Barbara J.
    Ro, Sunhee
    Donahue, Rafe
    Kawashima, Jun
    Mesa, Ruben
    LANCET, 2023, 401 (10373): : 269 - 280
  • [7] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib.
    Yacoub, Abdulraheem
    Stouffs, Michael
    Zhou, Feng
    Assad, Albert
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Efficacy and safety of neuronox for lateral canthal lines: a phase I/III, multicenter, randomized, double-blind, active-controlled study
    Lim, Youngkyoung
    Lee, Jong Hee
    Lee, Woo Shun
    Lee, Weon Ju
    Kim, Hei Sung
    Shin, Min Kyung
    Haw, Sik
    Huh, Chang-Hun
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (05) : 561 - 567
  • [9] A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
    Verstovsek, Srdan
    Mesa, Ruben A.
    Gotlib, Jason
    Levy, Richard S.
    Gupta, Vikas
    DiPersio, John F.
    Catalano, John V.
    Deininger, Michael
    Miller, Carole
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Arcasoy, Murat O.
    Hexner, Elizabeth
    Lyons, Roger M.
    Paquette, Ronald
    Raza, Azra
    Vaddi, Kris
    Erickson-Viitanen, Susan
    Koumenis, Iphigenia L.
    Sun, William
    Sandor, Victor
    Kantarjian, Hagop M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09): : 799 - 807
  • [10] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naive Myelofibrosis.
    Yacoub, Abdulraheem
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    CANCER RESEARCH, 2021, 81 (13)
12345